News : OTC

The company’s Universal Archive Platform provides strong results with expected cost savings in excess of $200,000.
ST. PAUL, Minn., Aug. 16, 2011—Digitiliti, Inc. (OTC: DIGI), a technology pioneer in information archiving software for unstructured data, today announced that a prominent pharmaceutical care solution provider...

Moberg Derma AB (publ.) has entered into a distribution agreement with Gebro Pharma AG S.A. for Emtrix® – for treatment of discolored and deformed nails resulting from fungal infection  (onychomycosis) or psoriasis, and Kaprolac® – for problems with dry and flaky skin and. Under the agreement, Gebro is granted exclusive rights to market and sell Emtrix®, Kaprolac® Dandruff Shampoo and Kaprolac® Scalp Solution in...

Moberg Derma AB today announced that a distribution agreement has been entered into with Laboratorio EDOL Produtos Farmaceuticos S.A. for Emtrix® – Moberg Derma’s product for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement EDOL is granted exclusive rights to market and sell Emtrix® in Portugal and ten markets in Africa and Central America. Moberg Derma will...

Moberg Derma’s market partner in the Nordic countries – Antula Healthcare, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals – has now launched sales of Nalox™ in the Nordic region. Pharmacies have displayed great interest in Moberg Derma’s product Nalox™ – a treatment for discoloured and damaged nails caused by nail fungus or nail psoriasis.

Moberg Derma AB, Sweden, today announced a commercial agreement for the Middle East. The agreement covers distribution in eight countries for Moberg Derma’s novel topical nail product Emtrix™ – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while the distributor will be responsible for registration...

Moberg Derma AB today announced that CE mark has been granted for its topical product for the management and relief of common scalp conditions associated with scaly and itchy skin, e.g. seborrhoeic eczema and dandruff. The CE mark provides authorization to market and sell the medical device product in the EU/EEA. The company also announced that it received ISO 13485 certification.

Moberg Derma AB today announced that CE-mark has been granted for the company’s first approved medical device product, used for the treatment of discolored and damaged nails, for example caused by nail fungus (onycomycosis) or nail psoriasis. The CE mark provides authorization to market and sell the product in the EU/EEA.
“The approval is a result of focused development work during several years and is an...

Moberg Derma AB today announces a license and co-promotion agreement with a leading Nordic OTC company for K101 - Moberg Derma’s novel treatment for nail fungus (onychomycosis). In the agreement, Moberg Derma will be responsible for supply of the product and promotion to prescribers, while its Nordic partner will be responsible for promotion to consumers. Financial terms are not disclosed but include up-front and...